HomeCompareTWEB vs ABBV

TWEB vs ABBV: Dividend Comparison 2026

TWEB yields 0.61% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $19.4K in total portfolio value
10 years
TWEB
TWEB
● Live price
0.61%
Share price
$22.02
Annual div
$0.13
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.5K
Annual income
$62.95
Full TWEB calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — TWEB vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTWEBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TWEB + ABBV cover 4 of 12 monthsgood coverage

Jan
ABBV
Feb
Mar
Apr
ABBV
May
Jun
Jul
ABBV
Aug
Sep
Oct
ABBV
Nov
Dec
TWEB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TWEB
Annual income on $10K today (after 15% tax)
$51.44/yr
After 10yr DRIP, annual income (after tax)
$53.51/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, ABBV beats the other by $927.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TWEB + ABBV for your $10,000?

TWEB: 50%ABBV: 50%
100% ABBV50/50100% TWEB
Portfolio after 10yr
$30.2K
Annual income
$608.70/yr
Blended yield
2.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TWEB
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TWEB buys
0
ABBV buys
0
No recent congressional trades found for TWEB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTWEBABBV
Forward yield0.61%3.67%
Annual dividend / share$0.13$6.20
Payout ratio50%58%
1-year div growth0%4.7%
5-year div CAGR0%8.9%
Portfolio after 10y$20.5K$39.9K
Annual income after 10y$62.95$1,154.43
Total dividends collected$618.00$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TWEB vs ABBV ($10,000, DRIP)

YearTWEB PortfolioTWEB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,761$60.52$11,520$399.75$759.00ABBV
2$11,575$60.86$13,261$450.98$1.7KABBV
3$12,446$61.19$15,255$508.41$2.8KABBV
4$13,379$61.49$17,536$572.74$4.2KABBV
5$14,377$61.77$20,145$644.78$5.8KABBV
6$15,445$62.04$23,126$725.38$7.7KABBV
7$16,589$62.29$26,532$815.52$9.9KABBV
8$17,813$62.52$30,420$916.26$12.6KABBV
9$19,122$62.74$34,855$1,028.80$15.7KABBV
10$20,524$62.95$39,914$1,154.43$19.4KABBV

TWEB vs ABBV: Complete Analysis 2026

TWEBStock

The index’s initial investible universe consists of equity securities listed on securities exchanges in the U.S., developed markets, and South Korea (the “Universe”). The Advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. It may invest in common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The fund’s investments may include small-, medium- and large-capitalization companies.

Full TWEB Calculator →

ABBVHealthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this TWEB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TWEB vs SCHDTWEB vs JEPITWEB vs OTWEB vs KOTWEB vs MAINTWEB vs JNJTWEB vs MRKTWEB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.